FOLFIRI Plus Durvalumab With or Without Tremelimumab as a Second-Line Treatment for Advanced Gastric or GEJ Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
JAMA Oncol 2024 Apr 04;[EPub Ahead of Print], D Tougeron, L Dahan, L Evesque, K Le Malicot, F El Hajbi, T Aparicio, O Bouché, N Bonichon Lamichhane, B Chibaudel, A Angelergues, A Bodere, JM Phelip, M Mabro, L Kaluzinski, C Petorin, G Breysacher, Y Rinaldi, A Zaanan, D Smith, MC Gouttebel, C Perret, N Etchepare, JF Emile, I Sanfourche, F Di Fiore, C Lepage, P Artru, C LouvetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.